Skip to main content
. Author manuscript; available in PMC: 2022 Jun 8.
Published in final edited form as: Urol Oncol. 2020 Dec 8;39(2):134.e1–134.e8. doi: 10.1016/j.urolonc.2020.11.019

Fig. 3.

Fig. 3.

Abnormalities of catecholamines and catecholamine byproducts by adrenal mass size. Patient were more likely to have catecholamine abnormalities as the mass increased in size. It is notable that the majority of adrenal masses less than 1 cm were not metabolically active.